| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2686 | 2011 |
| Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial S Kehoe, J Hook, M Nankivell, GC Jayson, H Kitchener, T Lopes, ... The Lancet 386 (9990), 249-257, 2015 | 1495 | 2015 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 983 | 2015 |
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial TM Suter, M Procter, DJ van Veldhuisen, M Muscholl, J Bergh, ... Journal of clinical oncology 25 (25), 3859-3865, 2007 | 715 | 2007 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 700 | 2017 |
| Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen J Adams, PJ Carder, S Downey, MA Forbes, K MacLennan, V Allgar, ... Cancer research 60 (11), 2898-2905, 2000 | 550 | 2000 |
| Automated collection of quality-of-life data: a comparison of paper and computer touch-screen questionnaires G Velikova, EP Wright, AB Smith, A Cull, A Gould, D Forman, T Perren, ... Journal of clinical oncology 17 (3), 998-998, 1999 | 438 | 1999 |
| Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies RE Banks, AJ Gearing, IK Hemingway, DR Norfolk, TJ Perren, PJ Selby British Journal of Cancer 68 (1), 122-124, 1993 | 404 | 1993 |
| Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... Journal of Clinical Oncology 38 (5), 423-433, 2020 | 344 | 2020 |
| Multiple myeloma treated with high dose intravenous melphalan PJ Selby, TJ McElwain, AC Nandi, TJ Perren, RL Powles, CR Tillyer, ... British journal of haematology 66 (1), 55-62, 1987 | 297 | 1987 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 296 | 2018 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 277 | 2022 |
| Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial JA Ledermann, AC Embleton, F Raja, TJ Perren, GC Jayson, GJS Rustin, ... The Lancet 387 (10023), 1066-1074, 2016 | 276 | 2016 |
| Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial JF Smyth, A Bowman, T Perren, P Wilkinson, RJ Prescott, KJ Quinn, ... Annals of oncology 8 (6), 569-573, 1997 | 276 | 1997 |
| Phase III multicenter clinical trial of the sialyl‐TN (STn)‐keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer D Miles, H Roché, M Martin, TJ Perren, DA Cameron, J Glaspy, D Dodwell, ... The oncologist 16 (8), 1092-1100, 2011 | 268 | 2011 |
| Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer JA Ledermann, A Hackshaw, S Kaye, G Jayson, H Gabra, I McNeish, ... Journal of Clinical Oncology 29 (28), 3798-3804, 2011 | 251 | 2011 |
| Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic … TRJ Evans, A Yellowlees, E Foster, H Earl, DA Cameron, AW Hutcheon, ... Journal of Clinical Oncology 23 (13), 2988-2995, 2005 | 248 | 2005 |
| Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis … AR Clamp, EC James, IA McNeish, A Dean, JW Kim, DM O'Donnell, ... The Lancet 394 (10214), 2084-2095, 2019 | 202 | 2019 |
| 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study M Wallington, EB Saxon, M Bomb, R Smittenaar, M Wickenden, S McPhail, ... The Lancet Oncology 17 (9), 1203-1216, 2016 | 200 | 2016 |
| The acute phase protein response in patients receiving subcutaneous IL-6 RE Banks, MA Forbes, M Storr, J Higginson, D Thompson, J Raynes, ... Clinical & Experimental Immunology 102 (1), 217-223, 1995 | 196 | 1995 |
JA LedermannProfessor of medical oncology, UCL Cancer Institute在 ucl.ac.uk 的电子邮件经过验证
